Testing a gentler stem cell transplant for children with sickle cell disease
Tests a lower-toxicity transplant using a sibling donor in children with sickle cell disease.
Key facts
- Who runs it
- Robert Nickel
- Where
- Charlotte, Chicago, Columbus, New York, and Washington D.C., United StatesSee the 5 sitesAlso in 1 other country, 2 sites
- Trial code
- Registry title
- Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 100 people, planned
- Started
- 17 Apr 2018
- Expected to end
- Nov 2030
- Type of study
- Interventional
- Treatments tested
- Alemtuzumab, low dose total body irradiation, Sirolimus
- Record updated
- 10 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people with sickle cell disease who have a healthy HLA-identical brother or sister as a stem cell donor. They must have had serious sickle cell complications.
- Age
- 2 Years to 25 Years
- Sex
- All sexes can join.
- Disease stage
- Sickle cell disease with serious past problems, such as an abnormal brain blood-flow scan, stroke, repeated acute chest syndrome, repeated pain events needing opiate or IV pain medication, priapism, regular red blood cell transfusions, or spleen sequestration.
- Earlier treatment
- Some people qualify through a hospital stay for pain or acute chest syndrome while on hydroxyurea, or through regular red blood cell transfusions (8 or more in the previous 12 months).
- Biomarker or test result
- Hemoglobin genotype SS, Sβ0 thalassemia, SC or Sβ+ thalassemia; the donor must be an HLA-identical sibling.
Main reasons for not taking part
- Life expectancy less than 6 months
- Pregnant or breastfeeding
- Uncontrolled infection, HIV, or active hepatitis B or C
- Serious liver, heart, kidney or lung problems as set out in the criteria
- Antibodies against the donor's red blood cells, or major ABO incompatibility with the donor
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Patients with genotypes hemoglobin SS and Sβ0 thalassemia must have at least one of the following:
- History of an abnormal transcranial Doppler measurement defined as TCD velocity ≥200 cm/sec by the non-imaging technique (or ≥185 cm/sec by the imaging technique) measured at a minimum of two separate occasions
- History of cerebral infarction on brain MRI (overt stroke, or silent stroke if ≥3 mm in one dimension, visible in two planes on fluid-attenuated inversion recovery T2-weighted images)
- History of two or more episodes of acute chest syndrome (ACS) in lifetime
- History of three or more SCD pain events requiring treatment with an opiate or IV pain medication (inpatient or outpatient) in lifetime
- History of any hospitalization for SCD pain or ACS while receiving hydroxyurea treatment
- History of two or more episodes of priapism (erection lasting ≥4 hours or requiring emergent medical care)
- Administration of regular RBC transfusions (≥8 transfusions in the previous 12 months)
- At least two episodes of splenic sequestration requiring red blood cell transfusion or splenectomy after at least one episode of splenic sequestration; Patients with all other sickle genotypes (hemoglobin SC, Sβ+ thalassemia) must have at least one of the following:
- Clinically significant neurologic event (overt stroke)
- History of two or more episodes of ACS in the 2-years period preceding enrollment
- History of three or more SCD pain events requiring treatment with an opiate or IV pain medication (inpatient or outpatient) in the 1-year period preceding enrollment
- History of any hospitalization for SCD pain or ACS while receiving hydroxyurea treatment
- History of two or more episodes of priapism (erection lasting ≥4 hours or requiring emergent medical care)
- Administration of regular RBC transfusions (≥8 transfusions in the previous 12 months)
- At least two episodes of splenic sequestration requiring red blood cell transfusion or splenectomy after at least one episode of splenic sequestration
Who cannot take part
- Infection Disease: Uncontrolled bacterial, viral or fungal infections (undergoing appropriate treatment and with progression of clinical symptoms) within 1 month prior to conditioning. Patients with febrile illness or suspected minor infection should await clinical resolution prior to starting conditioning. Patients with confirmed seropositivity for HIV and patients with active Hepatitis B or C determined by serology and/or NAAT are excluded
- Heme: History of RBC alloantibodies against donor RBC antigens (even if current antibody screen is negative). Major ABO incompatibility with donor
- Liver: Direct (conjugated) bilirubin > 1.5 mg/dL, transaminases >5x upper limit of normal for age
- Cardiac: Left ventricular shortening fraction <25% or ejection fraction <50% by ECHO
- Kidney: Estimated creatinine clearance less than 60 mL/min/1.73m2
- Pulmonary function: Diffusion capacity of carbon monoxide (DLCO) <35% (adjusted for hemoglobin). Baseline oxygen saturation <85% or PaO2 <70
- General: Life expectancy less than 6 months. Pregnant or breastfeeding patients
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 25 years old?
Where in United States
Also in 1 other country, 2 sites
- Levine Children's HospitalCharlotte, United StatesContact: Janice HollifieldTaking people
- Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United StatesContact: Olga JonasTaking people
- Nationwide Children's HospitalColumbus, United StatesContact: Hemalatha RangarajanTaking people
- Columbia UniversityNew York, United StatesContact: Jaclyn DosikTaking people
- Children's National Health SystemWashington D.C., United StatesContact: Maryanne OdinakachukwuTaking people
About the trial
What the trial wants to find out
This multisite prospective study seeks to determine if HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, "SUN") can decrease the toxicity of transplant while achieving a high cure rate for children with sickle cell disease (SCD).
The group in the trial
- SUN regimenTreatment being tested
Alemtuzumab, low dose total body irradiation, Sirolimus HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, "SUN") can decrease the toxicity of transplant while achieving a high cure rate for children with sickle cell disease (SCD).
Treatment: Alemtuzumab, low dose total body irradiation, Sirolimus
Results explained
A paper that names this trial, explained in plain words.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
- Plain-language title
- Testing a gentler stem cell transplant for children with sickle cell diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT03587272, who can take part
- Publications
- Record updated
- 10 March 2026